Catalyst Pharmaceuticals, Inc.
General ticker "CPRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.7B (TTM average)
Catalyst Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 18.6%.
Estimated limits based on current volatility of 1.2%: low 25.58$, high 26.23$
Factors to consider:
- Total employees count: 181 (+8.4%) as of 2024
- Top business risk factors: Product commercialization failure, Regulatory and compliance, Clinical trial delays, Cybersecurity threats, Geopolitical risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [18.69$, 28.44$]
- 2026-12-31 to 2027-12-31 estimated range: [19.99$, 30.21$]
Financial Metrics affecting the CPRX estimates:
- Positive: with PPE of 8.8 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 43.77 > 18.52
- Positive: 6.68 < Operating cash flow per share per price, % of 7.13
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term CPRX quotes
Long-term CPRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $398.20MM | $491.73MM | $588.99MM |
| Operating Expenses | $311.39MM | $296.61MM | $331.21MM |
| Operating Income | $86.81MM | $195.12MM | $257.78MM |
| Non-Operating Income | $7.70MM | $21.14MM | $25.74MM |
| R&D Expense | $93.15MM | $12.65MM | $12.71MM |
| Income(Loss) | $94.51MM | $216.26MM | $283.51MM |
| Taxes | $23.10MM | $52.37MM | $69.19MM |
| Profit(Loss)* | $71.41MM | $163.89MM | $214.33MM |
| Stockholders Equity | $387.88MM | $727.63MM | $954.27MM |
| Inventory | $15.64MM | $19.54MM | $37.17MM |
| Assets | $470.11MM | $851.41MM | $1,103.98MM |
| Operating Cash Flow | $143.60MM | $239.81MM | $208.67MM |
| Capital expenditure | $81.74MM | $0.56MM | $0.06MM |
| Investing Cash Flow | $-293.50MM | $-0.56MM | $-0.06MM |
| Financing Cash Flow | $-10.86MM | $140.66MM | $-16.99MM |
| Earnings Per Share** | $0.67 | $1.38 | $1.75 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.